Decongestion is an important goal of heart failure (HF) management. Blood cell concentration is a recognized indicator for guiding decongestive treatment for HF. We aimed to assess the clinical impact of hemodilution and hemoconcentration after initial treatment in acute decompensated HF (ADHF) patients. We retrospectively evaluated hemoglobin levels and body weight obtained before admission, on admission, 3 days after admission, and at discharge in 102 consecutive patients admitted with ADHF. Patients were then stratified into hemodilution (n = 55) and hemoconcentration (n = 47) groups based on whether their hemoglobin levels decreased or increased, respectively, during the first 3 days after admission. From before admission to admission, hemoglobin levels decreased less in the hemodilution group (-0.16 ± 0.98 g/dL) than in the hemoconcentration group (-0.88 ± 1.11 g/dL) (P < 0.001); however, there was no significant difference in body weight (P !0.05). More patients in the hemodilution group (85%) had grade III/IV pulmonary edema (Turner's criteria) compared with the hemoconcentration group (63%) (P < 0.01). Rate of readmission for HF within 180 days of discharge was higher in the hemodilution group (34%) compared with the hemoconcentration group (9%) (P < 0.01). Hemodilution after initial treatment for ADHF was associated with severe pulmonary edema at admission and higher readmission rates.
D
econgestion is an important goal in managing patients for treatment of heart failure (HF). [1] [2] [3] Congestion has been proposed as occurring via fluid accumulation, with increased intravascular fluid volume leading to increased intravascular pressure under congestive conditions. 4) However, more than half of all patients with acute decompensated HF (ADHF) have no clinical signs of fluid retention. 5) The relationship between congestion and intravascular fluid volume therefore remains unclear. Because red blood cells remain confined to the intravascular space, hemoglobin (Hb) levels can be used as a marker of intravascular fluid volume, unless bleeding or blood transfusion has occurred. 6) Hemodilution (HD) and hemoconcentration (HC) have emerged as indicators that can help guide inpatient decongestive therapy. In previous reports, HC-guided diuresis has been associated with lowered mortality and readmission rates. [7] [8] [9] However, the fluid volume in the intravascular space is known to be refilled from the interstitial tissues and to be continuously changing during therapy, and time of hemoconcentration varies among patients with HF. 10, 11) Testani, et al. have reported that only late HC, which is achieved after 4 days of hospitalization, had prognostic significance, whereas early HC, which is achieved before 4 days, did not. 11) On the contrary, Konishi, et al. reported that Hb levels were significantly decreased at 24 hours after ADHF treatment in patients with acute pulmonary edema. 12) The relationship between initial hemodilution following ADHF treatment and its outcomes is unclear. In this study, we therefore aimed to clarify the prognostic impact of temporal changes in intravascular fluid volume estimated by Hb during decongestive therapy in patients hospitalized with ADHF.
Methods

Subjects:
This was a single-center, retrospective, observational study of patients admitted to the Kitasato University Hospital in Japan between January 2012 and December 2014. Using the HF database at our institute, we screened patients with a diagnosis of ADHF defined according to the Framingham criteria. For inclusion, we required each subject to have their serum Hb levels and body weight (BW) recorded at 4 points: before admission; on admis-Fujita, ET AL Figure 1 . Study design. Hemoglobin (Hb) levels and body weights (BW) were obtained at 4 points: before admission; on admission; at 3 days after admission; and at discharge. sion; 3 days after admission; and at discharge (Figure 1 ). The exclusion criteria were death, cardiac surgery, hemodialysis, active bleeding or blood transfusion, chemotherapy, erythropoiesis-stimulating treatment, iron replacement therapy during admission and transfer to another hospital. All patients provided written informed consent for data collection. The registry protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in a priori approval by the institution's human research committee. Measurement: Data for before admission was obtained from outpatients who had clinically stable conditions !1 month before admission, and such data was recorded at the last visit to the clinic. Patients were stratified based on the change in Hb levels during the first 3 days after admission, as follows: change in Hb levels < 0 g/dL (HD group) and !0 g/dL (HC group).
9,11) Chest X-rays were obtained on admission and at 3 days after admission, and were compared for radiographic signs of pulmonary edema using established criteria. 13) B-type natriuretic peptide was obtained before admission, on admission, and at discharge. Echocardiography was performed with standard parasternal and apical views at admission. Outcomes were assessed as the rate of readmission for an exacerbation of HF up to 180 days after discharge. Statistical analysis: Data are presented as means ± standard deviations or as frequencies (percentages). Intergroup comparison was made using the Student's t-test or MannWhitney U-test. Pearson's χ 2 test was used to evaluate categorical variables. Paired-sample t-tests were used to compare continuous variables at admission with those from before admission, 3 days after admission, and at discharge. Two-tailed P-values less than 0.05 were considered to indicate statistically significant differences. The associations between subgroups and the prognostic outcomes were assessed using Cox proportional hazards analyses. Significant univariate predictors of outcome were subsequently entered into multivariate models. Kaplan-Meier survival plots for the readmission outcome (HF exacerbation) were constructed for both the HD and HC groups, and the observed differences in survival rates were tested using the log-rank test. JMP version 11 (SAS Institute, Cary, North Carolina, USA) was used for all analyses.
Results
Patient characteristics:
We initially screened 154 consecutive hospitalized patients with ADHF. Of these, 52 were excluded from our study for the following reasons: death (n = 7); cardiac surgery (n = 4); hemodialysis (n = 12), active bleeding or blood transfer (n = 19); chemotherapy, erythropoiesis-stimulating treatment or iron-intake treatment (n = 8); and transfer to another hospital (n = 2). Finally, 102 patients were included, with 55 (54%) in the HD group and 47 (46%) in the HC group ( Figure 2 ). As initial treatments during the first 3 days after admission, intravenous loop diuretics, carperitide, nitroglycerin and inotropes were used in 64 patients (63%), 22 patients (22%), 27 patients (27%), and 13 patients (13%), respectively; and noninvasive positive pressure ventilation/intubation was introduced in 10 patients (10%). HD group was treated with nitroglycerin more so than in HC group (41% in HD group versus 11% in HC group, P < 0.05); however, the dose of loop diuretics was not significantly different during the first 3 days after admission between the 2 groups (11 ± 11 mg/day in HD group versus 12 ± 10 mg/day in HC group, NS). The clinical characteristics are summarized in Table I . Temporal change in BW and Hb levels: Absolute changes in BW and Hb levels from before admission to discharge are shown in Figure 3 . The duration from before admission to admission was not significantly different between the 2 groups (128 ± 128 days in HD group versus 120 ± 165 days in HC group, P !0.05). There was no significant difference between the 2 groups in change in BW from the time before admission to admission (+2.1 ± 4.0 kg in HD group versus 1.9 ± 3.9 kg in HC group, P ! 0.05) or from admission to 3 days (-1.2 ± 1.3 kg in HD group versus -1.6 ± 1.7 kg in HC group, P !0.05). However, from before admission to admission, Hb levels decreased less in the HD group (-0.16 ± 0.98 g/dL) compared with the HC group (-0.88 ± 1.11 g/dL) (P < 0.001). Hb levels did not decrease from before admission (12.7 ± 2.1 g/dL) to admission (12.6 ± 2.3 g/dL) in the HD group (P !0.05), however they decreased significantly from before admission (12.2 ± 2.1 g/dL) to admission (11.4 ± 2.1 g/dL) in the HC group (P < 0.0001). Pulmonary edema in the HC and HD groups: The HD group had more radiographic evidence of severe pulmonary edema on admission compared with the HC group. Figure 4A shows that more patients had grade III or IV pulmonary edema in the HD group (85%) than in the HC group (63%) (P < 0.05), whereas Figure 4B shows that pulmonary edema improved more often in the HD group than in the HC group (P < 0.001). Outcomes: During the 180-day follow-up period, 22 patients (22%) were readmitted with an exacerbation of HF, and 3 of these patients (3%) died. Kaplan-Meier curves indicated higher rates of readmission for HF exacerbation in the HD group (P = 0.005, Figure 5 ). Table II summarizes the univariate and multivariate analyses of the prognostic factors reported in previous studies for the predicted readmission for HF exacerbation.
Discussion
We have reported 3 main findings in this study. First, despite BW decreasing in most patients with ADHF, approximately half of the patients showed a decrease in Hb levels during the first 3 days of admission. Second, in the patients with HD, pulmonary edema was severe on admission, however, this improved significantly during the first 3 days after admission. Third, we showed higher rates of readmission for HF exacerbation in patients with HD than in those with HC. Difference in the pathophysiological mechanisms of HC and HD: Our results indicated that changes in Hb levels after admission varied significantly among patients despite similar BW reductions after initial HF treatment. In the HC group, an increase in the Hb level was inversely correlated with a decrease in BW during the first 3 days of admission, which was considered a natural consequence of the loss of intravascular fluid volume. [14] [15] [16] [17] [18] Contrastingly, despite reduction in patient BW, Hb levels decreased in the HD group during the first 3 days of admission. This paradoxical phenomenon has been reported in previous studies. 19, 20) In those reports, it was speculated that acute decline in Hb levels reflected an increased rate of fluid volume returning to the intravascular compartment from the interstitial tissues due to a reduced capillary hydrostatic pressure induced by decongestion treatment with diuretics and vasodilators.
Congestion is thought to occur through 2 pathophysiological mechanisms: fluid accumulation (volume overload); and fluid redistribution (volume shift). 21) Fluid accumulation occurs via increased sodium and water retention, activation of the renin-angiotensin-aldosterone system, and increased sodium uptake. On the other hand, fluid redistribution may occur through reduced venous capacitance and activation of the sympathetic nervous system, leading to fluid shifting out of the splanchnic vessels to increase the circulating blood volume. Therefore, congestion can be caused without any changes in the total fluid volume. [21] [22] [23] During the period from before admission to admission, Hb levels decreased in the HC group, however, not in the HD group. This indicated that, in the HD group, the intravascular fluid volume was not increased from the time before admission to admission, and that congestion on admission might have been triggered by fluid redistribution rather than accumulation. Furthermore, heart rate and blood pressure were higher on admission in the HD group than in the HC group, suggesting that the sympathetic nervous system might be activated to a greater degree in the HD group. Relationship with HD and pulmonary edema: It has been reported that acute pulmonary edema is significantly associated with decreased Hb levels at 24 hours after treatment for ADHF. 12) Acute pulmonary edema in this setting is thought to be induced by increased capillary permeability and capillary hydrostatic pressure.
24) The capillary endothelial and alveolar epithelial layers are broken under acute pulmonary hypertension, and these changes lead to an increase in capillary permeability, [25] [26] [27] occasionally through fluid redistribution. In our study, the proportion of patients with radiographic signs of interstitial and alveolar edema was significantly higher in the HD group than in the HC group. Increased capillary hydrostatic pressure and permeability might have caused large amounts of edema to invade the interstitium and alveolar spaces. When the capillary transmural pressure reduced, disruption of the capillary endothelial and alveolar epithelial layers may have rapidly reversed, allowing rapid normalization of the capillary permeability. 28) Through such a physiological mechanism, fluid refill may have been immediate after initial treatment for ADHF, accounting for the decrease in Hb levels in the HD group during the first 3 days after admission. Compared with the HD group, capillary endothelial and alveolar epithelial layers might be preserved in the HC group. Hence, fluid refill may not have immediately occurred despite capillary hydrostatic pressure decreasing after the initial treatment for ADHF. Relationship between HD and prognosis in patients with HF: In our study, HD was an independent predictor of readmission for HF exacerbation during mid-term follow-up. This may be explained by the differences in 12 (12) 7 (15) 5 (9) 0.37 Tolvaptan, n (%) 9 (9) 4 (9) 5 (9) 0.92 IHD indicates ischemic heart disease; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; HHD, hypertensive heart disease; VHD, valvular heart disease; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; Af, atrial fibrillation; AFL, atrial flutter; MR, mitral regurgitation; and i.v., intravenous HEMOGLOBIN CHANGE FOR ADHF pathophysiological mechanisms of exacerbation of HF in the HC and HD groups. In the HC group, the pathophysiological process was primarily thought to be due to fluid accumulation. Therefore, congestion will have developed gradually, because it will have taken a long time for increasing pulmonary arterial pressure to develop by increased sodium and water retention. In the HD group, however, congestion probably occurred by fluid redistribution, which would reduce venous capacitance and activation of the sympathetic nervous system, leading to immediate pulmonary hypertension and increased capillary permeability. 21, 22) Previous studies have reported differences in clinical prognosis between the pathophysiological processes of acute HF and have showed that HF caused by 29, 30) Generally, HF caused by fluid accumulation is characterized by cardiac dysfunction (reduced left ventricular ejection fraction), whereas fluid redistribution is characterized by frequent vascular dysfunction (normal left ventricular ejection fraction). 29, 31, 32) However, the pathogenesis of acute HF caused by fluid redistribution is related to a decrease in cardiac systolic performance due to an immediate increase in the systemic vascular resistance; hence, cardiac function is important for fluid redistribution.
33) The HD group had reduced left ventricular ejection fraction, and there was no significant difference between the HD and HC groups (HD: 39 ± 16% versus HC: 45 ± 18%, P = 0.08). The HC group had cardiac dysfunction, however the HD group had both cardiac and vascular dysfunction. Thus, the HD group might have had a higher rate of readmission for HF exacerbation than that of the HC group.
We speculate that these differences contributed to the different readmission rates for HF exacerbation during mid-term follow-up.
Clinical implication: HC-guided diuretic therapy has been developed to improve clinical outcomes for ADHF. 9) Although diuretic treatment has been considered mandatory for relieving congestion induced by fluid accumulation, it may not be necessary to reduce congestion triggered by fluid redistribution.
Hence, patients with HF caused by fluid redistribution should be administered vasodilation therapy instead of the aggressive diuretic therapy. Additionally, carotid body modulation, vagal nerve stimulation, and carotid sinus stimulation may be useful for optimizing sympathetic nerve activity and preventing the reoccurrence of HF exacerbation for these patients. 22) To pay attention to the change or decrease of Hb levels after initial treatment for ADHF may help to identify the pathophysiological mechanisms of pulmonary congestion and aid in selecting treatment strategies for preventing HF exacerbation. Limitations: There were some important limitations in this research. First, it was a retrospective observational study, so it was impossible to demonstrate causality and exclude residual confounding. Second, we required BW and Hb levels before admission, so excluded patients with de novo ADHF episodes, and this may have caused selection bias. Third, differences in treatment during the first 3 days of admission may have influenced the outcomes. Furthermore, insufficient diuretic therapy did not increase but decreased Hb levels. Patients who received insufficient therapy may have been assigned to the HD group. However, the dose of loop diuretics was not significantly different during 3 days after admission between the HD and HC groups, and 49 patients (99%) showed decreased BW at 3 days after initial treatment for ADHF in the HD group. Fourth, a number of factors, such as albumin or total protein content, should be considered for defining hemodilution or hemoconcentration. However, we could not analyze these factors because of missing data. Therefore, prospective investigation is needed to validate our results.
Conclusion
Patients with ADHF and reduced Hb after initial treatment for HF are associated with a severe pulmonary edema on admission and poor clinical outcomes.
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